New chemo cocktail aims to fight childhood germ cell tumors that return
NCT ID NCT07662018
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well a combination of four chemotherapy drugs (gemcitabine, docetaxel, melphalan, and carboplatin) followed by a stem cell transplant works in children and teens up to age 21 whose germ cell tumors have come back or not responded to treatment. Researchers will track side effects and treatment outcomes in about 30 participants. The goal is to gather information that could help improve care for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gemcitabine, docetaxel, melphalan, carboplatin
What this could lead to
If successful, this combination could offer a treatment option for children whose germ cell tumors have returned or not responded to standard therapy.
What could go wrong
This is an observational study with a small group of 30 participants, so results may not apply broadly. The chemotherapy regimen carries risks of serious side effects, including infection and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact